long intergenic non-protein coding RNA 2600Genealiases: []
Q-omics provides the consensus-scored LINC02600 profile across patient tissues and cancer cell-line models. LINC02600 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02600 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC02600 RNA expression shows 15,223 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where LINC02600 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02600 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02600 survival associations across molecular data types. LINC02600 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02600 RNA expression–survival associations across cancer types. High LINC02600 expression shows unfavorable associations in LUAD and ACC, but favorable associations in KIRC, UVM, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02600 RNA expression.
This table summarizes LINC02600 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02600. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02600 shows lower tumor expression in KIRC, KICH, LUAD, UCEC, KIRP and BRCA. The KIRC box plot shows higher LINC02600 RNA expression in normal versus tumor tissue (log2 FC = −1.119, t-test p < 0.001).
This table shows molecular features associated with LINC02600 in patient tissues and cancer cell lines. In patient samples, LINC02600 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
